EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis

Igal Rosenstein iD, Markus Axelsson, Magnus Johnsson iD, Clas Malmeström iD, Hlin Kvartsberg, Henrik Zetterberg, Jan Lycke, Lenka Novakova

European Journal of Neurology · 2026

DOI: 10.1111/ene.70602 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Igal Rosenstein und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Dimethyl Fumarate, Natalizumab, Immunoglobulin kappa-Chains, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Society of the Neurologically Disabled, Research Foundation of the Multiple Sclerosis Society of Gothenburg, Edit Jacobson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cerebrospinal fluid (CSF) kappa free light chains (KFLC) is a sensitive marker of intrathecal immunoglobulin synthesis and is incorporated into the 2024 McDonald criteria for multiple sclerosis (MS). How disease‐modifying therapies (DMTs) influence KFLC dynamics and their association with treatment response remains unclear.

Objective

To determine whether intrathecal KFLC synthesis changes during DMT and whether these changes are associated with clinical outcomes.

Methods

Patients with treatment‐naïve relapsing–remitting MS were prospectively enrolled at the Sahlgrenska MS Center (Gothenburg, Sweden). Paired CSF and serum samples were collected at baseline and after 12 months of treatment with dimethyl fumarate (DMF) or natalizumab (NTZ). KFLC index was calculated as [(CSF KFLC/serum KFLC)/(CSF albumin/serum albumin)]. Treatment response was assessed using no evidence of disease activity‐3 (NEDA‐3) and progression independent of relapse and MRI activity (PIRMA + ).

Results

Forty‐eight patients were included (DMF n = 26, NTZ n = 22). NTZ reduced KFLC index from a median 117.4 (63.6–171.9) at baseline to 78.8 (39.4–104.0) at 12 months (adjusted p = 0.003), corresponding to a median decline of −51.0 (IQR −82.1 to −24.7), whereas DMF produced no meaningful change. In NTZ‐treated patients maintaining NEDA‐3 or without PIRMA + , KFLC index declined markedly (both p < 0.01). Change in KFLC index predicted outcomes, yielding an AUC of 1.0 for NEDA‐3 and 0.79 for non‐PIRMA + .

Conclusions

Natalizumab appears to reduce intrathecal KFLC synthesis, and a decline in KFLC index may reflect effective suppression of CNS humoral immunity. ΔKFLC index could serve as a sensitive biomarker of treatment response and disease stability in MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dimethyl FumarateNatalizumabImmunoglobulin kappa-ChainsMultiple Sclerosis, Relapsing-RemittingImmunologic FactorsHumansFemaleMaleAdultDisease ProgressionBiomarkersTreatment OutcomeMiddle AgedImmunosuppressive AgentsProspective StudiesInflammation

Stichwörter der Autor:innen

biomarkersimmunologic factorsneurodegenerationneuroinflammationtreatment outcome

Substanzen

Dimethyl FumarateNatalizumabImmunoglobulin kappa-ChainsBiomarkersImmunologic FactorsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Region Västra Götaland, Sahlgrenska University Hospital, Department of Neurology, Gothenburg, Sweden.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
  • UK Dementia Research Institute at UCL, London, UK.
  • Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

ORCID-Profile: Igal Rosenstein, Magnus Johnsson, Clas Malmeström

Förderung

  • Swedish Society of the Neurologically Disabled
  • Research Foundation of the Multiple Sclerosis Society of Gothenburg
  • Edit Jacobson Foundation
  • Swedish Foundation for MS Research
  • G #x00F6; teborgs L #x00E4; kares #x00E4; llskap
  • Göteborgs Läkaresällskap

Zitieren

APA

Rosenstein, I., Axelsson, M., Johnsson, M., Malmeström, C., Kvartsberg, H., Zetterberg, H., Lycke, J., & Novakova, L. (2026). Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.70602

Vancouver

Rosenstein I, Axelsson M, Johnsson M, Malmeström C, Kvartsberg H, Zetterberg H, et al. Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis. European Journal of Neurology. 2026. doi:10.1111/ene.70602

BibTeX
@article{Rosenstein2026,
  author = {Rosenstein, Igal and Axelsson, Markus and Johnsson, Magnus and Malmeström, Clas and Kvartsberg, Hlin and Zetterberg, Henrik and Lycke, Jan and Novakova, Lenka},
  title = {Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70602}
}
Kostenlos starten →